Pacira BioSciences (PCRX): Viatris to buy it for $1.65B in cash
Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, a ~44.8% premium to its last close. Pacira's non-opioid pain drugs Exparel and…
Home/Companies/Pacira BioSciences (PCRX)
Pacira BioSciences (PCRX)
2 takes
All Centiview takes on Pacira BioSciences (ticker PCRX): earnings, deals and market news, newest first. Filed under Healthcare; region: US. Each take lists its sources. For information only, not advice.
Pacira BioSciences (PCRX): Viatris to buy it for $1.65B in cash at $36.50 a share
Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, a 44.8% premium to its last close. The deal adds non-opioid pain drugs Exparel…